Proteopedia - User contributions [en]

Sandbox Reserved 190

2014-04-23T23:33:40Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3GRO' size='340' side='right' caption='HDSF Binding' scene=''>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

==Inhibitors of PPT-1==
'''<scene name='43/436866/Overall-3-rainbow/1'>PPT-1</scene>''' is a lysosomal enzyme which had a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. <scene name='58/580839/Hdsf_by_itself/1'>Hexadecylsulfonylfluoride</scene> (HDSF) is a serine-modifying reagent that is able to inhibit the actions of PPT1 <scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>. Unlike other inhibitors, <scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene> leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT1. The sulphur of HDSF will <scene name='58/580839/Hdsf_bound_to_ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene> via a sulponylation reaction and thus will inhibit the actions of PPT-1.

==Disease Associated With PPT-1==

Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations of the PPT-1 enzyme. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the ''1p32'' chromosome have been identified to cause INCL.
[[Image:All_mutations.jpg|100px|right|thumb|Mutations Associated with INCL]]

Juvenile NCL (JNCL) and Late-infantile NCL (LINCL)are less severe forms of INCL in which onset of symptoms occur much later in life, between the ages of 30-40. The mutations associated with JNCL and LINCL occur away from the active site of PPT-1 resulting in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75.
[[Image:Thr-_mut.png|200px|right|thumb|Common Mutation associated with JNCL and LINCL involve mutations Far Away From Active Site]]

(Bellizzi J. Widom J. Kemp. Lu J. Das K. Hofmann L. Jon Clardy J. 2000. The crystal structure of palmitoyl protein thioesterase1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Biochemistry. 97: 4573-4578)

Unfortunately not much is known on how to treat INCL. However, in both JNCL and LINCL activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way in which to increase the activity of PPT-1 is to use protein chaperons that help refold PPT-1 in the endoplasmic reticulm. Although this is not a cure for INCL, by increasing the activity of PPT-1 the life expectancy for individuals with INCL can be greatly increased.

(Dawson G. Schroeder C. Dawson P. 2010. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem and Biophys Research Comm. 395. 66-69.)

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>binds to SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-good/1'>TextToBeDisplayed</scene>
</StructureSection>

Sandbox Reserved 190

2014-04-03T00:04:54Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3GRO' size='340' side='right' caption='HDSF Binding' scene=''>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

==Inhibitors of PPT-1==
'''<scene name='43/436866/Overall-3-rainbow/1'>PPT-1</scene>''' is a lysosomal enzyme which had a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. <scene name='58/580839/Hdsf_by_itself/1'>Hexadecylsulfonylfluoride</scene> (HDSF) is a serine-modifying reagent that is able to inhibit the actions of PPT1 <scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>. Unlike other inhibitors, <scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene> leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT1. The sulphur of HDSF will <scene name='58/580839/Hdsf_bound_to_Ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene> via a sulponylation reaction and thus will inhibit the actions of PPT-1.

==Disease Associated With PPT-1==

Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations of the PPT-1 enzyme. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the ''1p32'' chromosome have been identified to cause INCL.
[[Image:All_mutations.jpg|100px|right|thumb|Mutations Associated with INCL]]

Juvenile NCL (JNCL) and Late-infantile NCL (LINCL)are less severe forms of INCL in which onset of symptoms occur much later in life, between the ages of 30-40. The mutations associated with JNCL and LINCL occur away from the active site of PPT-1 resulting in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75.
[[Image:Thr-_mut.png|200px|right|thumb|Common Mutation associated with JNCL and LINCL involve mutations Far Away From Active Site]]

(Bellizzi J. Widom J. Kemp. Lu J. Das K. Hofmann L. Jon Clardy J. 2000. The crystal structure of palmitoyl protein thioesterase1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Biochemistry. 97: 4573-4578)

Unfortunately not much is known on how to treat INCL. However, in both JNCL and LINCL activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way in which to increase the activity of PPT-1 is to use protein chaperons that help refold PPT-1 in the endoplasmic reticulm. Although this is not a cure for INCL, by increasing the activity of PPT-1 the life expectancy for individuals with INCL can be greatly increased.

(Dawson G. Schroeder C. Dawson P. 2010. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem and Biophys Research Comm. 395. 66-69.)

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>binds to SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene>
<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-good/1'>TextToBeDisplayed</scene>
</StructureSection>

File:Thr- mut.png

2014-04-02T23:55:17Z

Kelly Maddalone:

Sandbox Reserved 190

2014-04-02T23:54:39Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3GRO' size='340' side='right' caption='HDSF Binding' scene=''>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

==Inhibitors of PPT-1==
'''<scene name='43/436866/Overall-3-rainbow/1'>PPT-1</scene>''' is a lysosomal enzyme which had a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. <scene name='58/580839/Hdsf_by_itself/1'>Hexadecylsulfonylfluoride</scene> (HDSF) is a serine-modifying reagent that is able to inhibit the actions of PPT1 <scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>. Unlike other inhibitors, <scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene> leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT1. The sulphur of HDSF will <scene name='58/580839/Hdsf_bound_to_Ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene> via a sulponylation reaction and thus will inhibit the actions of PPT-1.

==Disease Associated With PPT-1==

Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decreases in PPT-1 activity due to mutations of the PPT-1 enzyme. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the 1p32 chromosome have been identified to cause INCL.
[[Image:All_mutations.jpg|100px|right|thumb|Mutations Associated with INCL]]

Juvenile NCL (JNCL) and Late-infantile NCL (LINCL)are less severe forms of INCL in which onset of symptoms occur much later in life, between the ages of 30-40. The mutations associated with JNCL and LINCL occur away from the active site of PPT-1 resulting in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75.
IMAGE!!!!

(Bellizzi J. Widom J. Kemp. Lu J. Das K. Hofmann L. Jon Clardy J. 2000. The crystal structure of palmitoyl protein thioesterase1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Biochemistry. 97: 4573-4578)

Unfortunately not much is known on how to treat INCL. However, in both JNCL and LINCL activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way in which to increase the activity of PPT-1 is to use protein chaperons that help refold PPT-1 in the endoplasmic reticulm. Although this is not a cure for INCL, by increasing the activity of PPT-1 the life expectancy for individuals with INCL can be greatly increased.

(Dawson G. Schroeder C. Dawson P. 2010. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem and Biophys Research Comm. 395. 66-69.)

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>binds to SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene>
<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-good/1'>TextToBeDisplayed</scene>
</StructureSection>

File:All mutations.jpg

2014-04-02T23:45:54Z

Kelly Maddalone:

Sandbox Reserved 190

2014-04-02T19:40:23Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3GRO' size='340' side='right' caption='HDSF Binding' scene=''>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

==Inhibitors of PPT-1==
'''<scene name='43/436866/Overall-3-rainbow/1'>PPT-1</scene>''' is a lysosomal enzyme which had a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. <scene name='58/580839/Hdsf_by_itself/1'>Hexadecylsulfonylfluoride</scene> (HDSF) is a serine-modifying reagent that is able to inhibit the actions of PPT1 <scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>. Unlike other inhibitors, <scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene> leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT1. The sulphur of HDSF will <scene name='58/580839/Hdsf_bound_to_Ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene> via a sulponylation reaction and thus will inhibit the actions of PPT-1.

==Disease Associated With PPT-1==

Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decreases in PPT-1 activity due to mutations of the PPT-1 enzyme. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the 1p32 chromosome have been identified to cause INCL.

Juvenile NCL (JNCL) and Late-infantile NCL (LINCL)are less severe forms of INCL in which onset of symptoms occur much later in life, between the ages of 30-40. The mutations associated with JNCL and LINCL occur away from the active site of PPT-1 resulting in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75.
IMAGE!!!!

(Bellizzi J. Widom J. Kemp. Lu J. Das K. Hofmann L. Jon Clardy J. 2000. The crystal structure of palmitoyl protein thioesterase1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Biochemistry. 97: 4573-4578)

Unfortunately not much is known on how to treat INCL. However, in both JNCL and LINCL activity of PPT-1, there is only a small, 2%, increase in PPT-1 activity compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way in which to increase the activity of PPT-1 is to use protein chaperons that help refold PPT-1 in the endoplasmic reticulm. Although this is not a cure for INCL, by increasing the activity of PPT-1 the life expectancy for individuals with INCL can be greatly increased.

(Dawson G. Schroeder C. Dawson P. 2010. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem and Biophys Research Comm. 395. 66-69.)

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>binds to SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene>
<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-good/1'>TextToBeDisplayed</scene>
</StructureSection>

Sandbox Reserved 190

2014-04-02T19:11:57Z

Kelly Maddalone:

Sandbox Reserved 190

2014-03-28T18:20:37Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3GRO' size='340' side='right' caption='HDSF Binding' scene=''>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>HDSF binds to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF can fit in the small narrow groove of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>HDSF Binds To SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-best/1'>HDSF Binds to SER-115 </scene>
<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115-good/1'>TextToBeDisplayed</scene>
</StructureSection>

Sandbox Reserved 190

2014-03-28T18:06:20Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3GRO' size='340' side='right' caption='HDSF Binding' scene=''>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>HDSF binds to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF can fit in the small narrow groove of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>HDSF Binds To SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

</StructureSection>

Sandbox Reserved 190

2014-03-28T18:04:58Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3rec' size='340' side='right' caption='HDSF Binding' scene='>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>HDSF binds to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF can fit in the small narrow groove of PPT-1</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>HDSF Binds To SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

Sandbox Reserved 190

2014-03-28T18:02:03Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3rec' size='340' side='right' caption='HDSF Binding' scene='>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/4'>HDSF binds to PPT-1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/1'>HDSF is able to fit into small groove</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>HDSF Binds To SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

Sandbox Reserved 190

2014-03-28T17:59:28Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3rec' size='340' side='right' caption='HDSF Binding' scene='>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/1'>HDSF Binds to PPT1</scene>'

<scene name='58/580839/Basic-hdsf-surfacelook/1'>HDSF is able to fit into small groove</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>HDSF Binds To SER-115 in the active site of PPT-1</scene>

<scene name='58/580839/Hdsf_with_ser/2'>HDSF with Ser-115</scene>

Sandbox Reserved 190

2014-03-28T17:50:32Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3rec' size='340' side='right' caption='HDSF Binding' scene='>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Hdsf_by_itself/1'>HDSF</scene>

<scene name='58/580839/Basic-hdsf-nosurface/1'>HDSF Binds to PPT1</scene>'

<scene name='58/580839/Basic-hdsf-surfacelook/1'>HDSF is able to fit into small groove</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>HDSF Binds To SER-115 in the active site of PPT-1</scene>

Sandbox Reserved 190

2014-03-28T17:16:22Z

Kelly Maddalone:

==PPT-1==
<StructureSection load='3rec' size='340' side='right' caption='HDSF Binding' scene='>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Basic-hdsf-nosurface/1'>HDSF Binds to PPT1</scene>'

<scene name='58/580839/Basic-hdsf-surfacelook/1'>HDSF is able to fit into small groove</scene>

<scene name='58/580839/Hdsf_bound_to_ser-115/1'>HDSF Binds To SER-115 in the active site of PPT-1</scene>

Sandbox Reserved 190

2014-03-28T16:36:38Z

Kelly Maddalone:

Sandbox Reserved 190

2014-03-21T18:52:52Z

Kelly Maddalone:

==Your Heading Here (maybe something like 'Structure')==
<StructureSection load='3rec' size='340' side='right' caption='Caption for this structure' scene=''>

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Sandbox Reserved 190'''

<scene name='58/580839/Basic-hdsf-nosurface/1'>HDSF Binds to PPT1</scene>

<scene name='58/580839/Basic-hdsf-surfacelook/1'>HDSF is able to fit into small groove</scene>

Sandbox Reserved 190

2014-03-21T17:55:19Z

Kelly Maddalone: New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='3rec' size='340' side='right' caption='Caption for this structure' scene=''> Anything in this section wil...

User:Kelly Maddalone/Sandox 1

2014-03-07T18:45:55Z

Kelly Maddalone:

[[Image:RNase_image.jpg|100px|left|thumb|RNase A]]
=='''RNase Structure'''==
<StructureSection load='7RSA' size='340' side='right' caption='Caption for this structure' scene=''>

== Functions ==

=== Gene Transcription ===

== Biological Disease ==

== Inhibitors ==

Anything in this section will appear adjacent to the 3D structure and will be <scene name='57/579556/Rnase_12_residue_amino_acid/2'>scrollable</scene>.
This is a default text for your page '''Kelly Maddalone/Sandox 1'''

</StructureSection>

User:Kelly Maddalone/Sandox 1

2014-03-07T18:31:27Z

Kelly Maddalone:

[[Image:RNase_image.jpg|100px|left|thumb|RNase A]]
=='''RNase Structure'''==
<StructureSection load='7RSA' size='340' side='right' caption='Caption for this structure' scene=''>

== Functions ==

=== Gene Transcription ===

== Biological Disease ==

== Inhibitors ==

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Kelly Maddalone/Sandox 1'''

</StructureSection>

User:Kelly Maddalone/Sandox 1

2014-03-07T18:25:40Z

Kelly Maddalone:

[[Image:RNase_image.jpg|100px|left|thumb|Figure Legend]]
=='''RNAase Structure'''==
<StructureSection load='3rec' size='340' side='right' caption='Caption for this structure' scene=''>

== Functions ==

=== Gene Transcription ===

== Biological Disease ==

== Inhibitors ==

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Kelly Maddalone/Sandox 1'''

</StructureSection>

File:RNase image.jpg

2014-03-07T18:17:18Z

Kelly Maddalone:

User:Kelly Maddalone/Sandox 1

2014-03-07T18:16:29Z

Kelly Maddalone:

=='''RNAase Structure'''==
<StructureSection load='3rec' size='340' side='right' caption='Caption for this structure' scene=''>

== Functions ==

=== Gene Transcription ===

== Biological Disease ==

== Inhibitors ==

Anything in this section will appear adjacent to the 3D structure and will be scrollable.
This is a default text for your page '''Kelly Maddalone/Sandox 1'''

</StructureSection>

User:Kelly Maddalone/Sandox 1

2014-03-07T18:04:31Z

User:Kelly Maddalone

2014-03-07T18:03:30Z

Kelly Maddalone:

* Full Real Name: Kelly Maddalone

* Position: Student

* Institution (NO ABBREVIATIONS): Butler University

* City, State/Province, Country: Indianapolis, IN, USA

* Field of Expertise or Study: CH462- Biochemistry

[[User:Kelly Maddalone/Sandox 1]]